



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to  
Lancet Infect Dis 2022;  
published online Nov 29.  
[https://doi.org/10.1016/  
S1473-3099\(22\)00660-0](https://doi.org/10.1016/S1473-3099(22)00660-0)**

Kumeso VKB, Mutombo Kalonji W, Rembry S, et al. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by *Trypanosoma brucei gambiense*: a multicentre, open-label, single-arm, phase 2/3 trial. *Lancet Infect Dis* 2022; published online Nov 29. [https://doi.org/10.1016/S1473-3099\(22\)00660-0](https://doi.org/10.1016/S1473-3099(22)00660-0)—In this Article, the inclusion criteria should have been “a Karnofsky score greater than 50” throughout the Article. This correction has been made to the online version as of Dec 19, 2022, and will be made to the printed version.

**Correction to  
Lancet Infect Dis 2022;  
published online Nov 18.  
[https://doi.org/10.1016/  
S1473-3099\(22\)00733-2](https://doi.org/10.1016/S1473-3099(22)00733-2)**

Arora P, Kempf A, Nehlmeier I, et al. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. *Lancet Infect Dis* 2022; published online Nov 18. [https://doi.org/10.1016/S1473-3099\(22\)00733-2](https://doi.org/10.1016/S1473-3099(22)00733-2)—In this Correspondence, in the figure the number above the fifth column under Pre S1–S2 should have read 679. This correction has been made to the online version as of Nov 29, 2022, and will be made to the printed version.

**Correction to  
Lancet Infect Dis 2022;  
22: 1052–61**

Sehgal IS, Dhooria S, Muthu V, et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India. *Lancet Infect Dis* 2022; 22: 1052–61—In this Article, the first patient was recruited on Feb 14, 2019, the last patient was recruited on Aug 30, 2019, and the last follow-up was completed on Aug 31, 2021. These corrections have been made to the online version as of Nov 29, 2022.



Published Online  
December 19, 2022  
[https://doi.org/10.1016/  
S1473-3099\(22\)00859-3](https://doi.org/10.1016/S1473-3099(22)00859-3)



Published Online  
November 29, 2022  
[https://doi.org/10.1016/  
S1473-3099\(22\)00802-7](https://doi.org/10.1016/S1473-3099(22)00802-7)



Published Online  
November 29, 2022  
[https://doi.org/10.1016/  
S1473-3099\(22\)00804-0](https://doi.org/10.1016/S1473-3099(22)00804-0)